News Sentiment
-50.0
Negative
DATA LIVE
Loading ...
Asset-specific news intelligence
Bristol-Myers Squibb Co.
Aggregated sentiment, estimated market impact and analysis confidence from recent articles linked to this asset. This feature is independent of the overall stock score.
All recent articles have completed sentiment assessments.
As of
Aug 21, 2026, 12:52 AM
News Sentiment
-50.0
Negative
Estimated Impact
60.0
Weighted estimate of how strongly the analyzed news may affect the asset.
Analysis Confidence
85.0
Confidence in the asset-specific article assessments, not historical model reliability.
Processing state of all articles inside the selected window.
Articles
1
Available
1
Pending
0
Failed
0
Unassessed
0
Latest analyzed article
Aug 15, 2026, 4:37 AM
Counts include only articles with an available assessment.
Positive
0
Neutral
0
Negative
1
High impact
0
Latest article
Aug 14, 2026, 7:26 PM
Showing 1–1 of 1 articles
AbbVie and Bristol-Myers Squibb are compared as dividend-paying pharmaceutical investments. AbbVie shows stronger revenue growth (8.6% YoY) driven by Skyrizi and Rinvoq, while Bristol-Myers Squibb faces patent cliff headwinds despite trading at a significant valuation discount. The article recommends AbbVie for long-term investors due to its focused operations, accelerating neuroscience portfolio, and attractive dividend, despite Bristol-Myers Squibb's recovery potential.
Analysis summary
The article compares Bristol-Myers Squibb unfavorably to AbbVie, highlighting BMY's patent cliff headwinds and recommending AbbVie over BMY despite BMY's valuation discount. This comparison implies a negative outlook for BMY relative to its peer, reducing investor confidence in the asset's near-term prospects.